AEMD / Aethlon Medical, Inc. - SEC-Einreichungen, Jahresbericht, Proxy Statement

Up to $542,716 Common Stock

PROSPECTUS SUPPLEMENT (To Prospectus Dated January 2, 2026) As Filed Pursuant to Rule 424(b)(5) Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2026 Aethlon Medical, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2026 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2026 Aethlon Medical, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2026 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2026 Aethlon Medical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2026 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission F

FRANCISCO V. AGUILAR Secretary of State 401 North Carson Street Carson City, Nevada 89701 - 4201 (775) 684 - 5708 Website: www.nvsos.gov Profit Corporation: Certificate of Amendment (PURSUANT TO NRS 78.380 & 78.385/78.390) Certificate to Accompany Re

Exhibit 3.1 FRANCISCO V. AGUILAR Secretary of State 401 North Carson Street Carson City, Nevada 89701 - 4201 (775) 684 - 5708 Website: www.nvsos.gov Profit Corporation: Certificate of Amendment (PURSUANT TO NRS 78.380 & 78.385/78.390) Certificate to Accompany Restated Articles or Amended and Restated Articles (PURSUANT TO NRS 78.403) Officer's Statement (PURSUANT TO NRS 80.030) TYPE OR PRINT - USE

Aethlon Medical, Inc. 2020 Equity Incentive Plan Adopted by the Board of Directors: February 6, 2020 Approved by the Stockholders: September 15, 2020 Amended by the Board: March 24, 2022 Amended by the Board: July 15, 2022 Approved by the Stockholder

Exhibit 10.1 Aethlon Medical, Inc. 2020 Equity Incentive Plan Adopted by the Board of Directors: February 6, 2020 Approved by the Stockholders: September 15, 2020 Amended by the Board: March 24, 2022 Amended by the Board: July 15, 2022 Approved by the Stockholders: September 15, 2022 Amended by the Board: August 6, 2024 Approved by the Stockholders: September 27, 2024 Amended by the Board: Decembe

Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET

Exhibit 99.1 Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, February 12, 2026 - Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2026 Aethlon Medical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2026 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 ☐ TRANSITION REPOR

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini

2,031,024 Shares of Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-292598 PROSPECTUS SUPPLEMENT No. 1 (To Prospectus dated January 16, 2026) 2,031,024 Shares of Common Stock This prospectus supplement relates to the prospectus dated January 16, 2026, as amended and supplemented from time to time (the “Prospectus”), which permits the resale from time to time, by the selling securityholders in this prospectus un

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2026 Aethlon Medical,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2026 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission Fi

AMENDMENT TO SECURITIES PURCHASE AGREEMENT

Exhibit 10.1 AMENDMENT TO SECURITIES PURCHASE AGREEMENT This AMENDMENT TO SECURITIES PURCHASE AGREEMENT (this “Amendment”), effective as of January 22, 2026 (the “Amendment Effective Date”), is by and between Armistice Capital, LLC or its assigns (“Holder”) and Aethlon Medical, Inc., a Nevada corporation (the “Company”), and amends that certain Securities Purchase Agreement dated December 5, 2025,

AMENDMENT TO PRE-FUNDED COMMON STOCK PURCHASE WARRANT

Exhibit 10.2 AMENDMENT TO PRE-FUNDED COMMON STOCK PURCHASE WARRANT This AMENDMENT TO PRE-FUNDED COMMON STOCK PURCHASE WARRANT (this “Amendment”), effective as of January 22, 2026 (the “Amendment Effective Date”), is by and between Armistice Capital, LLC or its assigns (“Holder”) and Aethlon Medical, Inc., a Nevada corporation (the “Company”), and amends that certain Pre-Funded Common Stock Purchas

2,031,024 Shares of Common Stock

AETHLON MEDICAL, INC. S-1 Filed Pursuant to Rule 424(b)(3) Registration No. 333-292598 PROSPECTUS 2,031,024 Shares of Common Stock This prospectus relates to the resale from time to time, by the selling securityholders in this prospectus under the caption “Selling Securityholders” of up to 2,031,024 shares of our common stock, par value $0.001 per share consisting of (1) (a) 1,042,820 shares of ou

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini

Filing Fee Table

Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-1 AETHLON MEDICAL, INC. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock Un

As filed with the Securities and Exchange Commission on January 7, 2026.

Table of Contents As filed with the Securities and Exchange Commission on January 7, 2026.

LETTER

December 30, 2025 James B. Frakes Chief Financial Officer Aethlon Medical, Inc. 11555 Sorrento Valley Road, Suite 203 San Diego, CA 92121 Re: Aethlon Medical, Inc. Registration Statement on Form S-3 December 23, 2025 File No. 333-292405 Dear James B. Frakes: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding

Aethlon Medical, Inc. 11555 Sorrento Valley Road, Suite 203 San Diego, CA 92121

Aethlon Medical, Inc. 11555 Sorrento Valley Road, Suite 203 San Diego, CA 92121 December 30, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Aethlon Medical, Inc. Registration Statement on Form S-3 Filed December 23, 2025 File No. 333-292405 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities

As filed with the Securities and Exchange Commission on December 23, 2025

Table of Contents As filed with the Securities and Exchange Commission on December 23, 2025 Registration No.

CALCULATION OF FILING FEE TABLES AETHLON MEDICAL, INC. Table 1: Newly Registered and Carry Forward Securities

Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-3 AETHLON MEDICAL, INC. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock, $

[remainder of page intentionally left blank]

Exhibit 4.2 December 19, 2025 Aethlon Medical, Inc. 11555 Sorrento Valley Road, Suite 203 San Diego, CA 92121 Attention: James Frakes, Chief Executive Officer and Chief Financial Officer Dear Mr. Frakes: Reference is made to the At The Market Offering Agreement, dated as of March 24, 2022 (collectively, the “ATM Agreement”), by and between Aethlon Medical, Inc. (the “Company”) and H.C. Wainwright

COMMON STOCK PURCHASE WARRANT AETHLON MEDICAL, INC.

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million

Exhibit 99.1 Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million SAN DIEGO, December 5, 2025 /PRNewswire/ - Aethlon Medical, Inc. (“Aethlon” or the “Company”) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today annou

AETHLON MEDICAL, INC. 11555 Sorrento Valley Road, Suite 203 San Diego, CA 92121

Exhibit 10.3 AETHLON MEDICAL, INC. 11555 Sorrento Valley Road, Suite 203 San Diego, CA 92121 December 5, 2025 To the Holder of September 2025 Common Warrants Re: Inducement Offer to Exercise Common Warrants Dear Holder: Aethlon Medical, Inc. (the “Company”) is pleased to offer to you the opportunity to exercise all the common warrants to purchase shares of the Company’s common stock, par value $0.

PLACEMENT AGENCY AGREEMENT December 5, 2025

Exhibit 1.1 PLACEMENT AGENCY AGREEMENT December 5, 2025 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), Aethlon Medical, Inc., a Nevada corporation (the “Company”), hereby agrees to sell up to an aggregate of $2,403,700 of shares (the “Shares”) of the Company’s common stock $0.001 par value per shar

REGISTRATION RIGHTS AGREEMENT

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 5, 2025, between Aethlon Medical, Inc., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase

PRE-FUNDED COMMON STOCK PURCHASE WARRANT AETHLON MEDICAL, INC.

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2025 Aethlon Medical,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2025 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission Fi

SECURITIES PURCHASE AGREEMENT

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 5, 2025, between Aethlon Medical, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions s

PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT AETHLON MEDICAL, INC.

Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2025 Aethlon Medical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2025 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission F

Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update Clinical and research progress continues alongside substantial cost reductions. Conference Call Today at 4:30 p.m. ET

Exhibit 99.1 Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update Clinical and research progress continues alongside substantial cost reductions. Conference Call Today at 4:30 p.m. ET SAN DIEGO, November 12, 2025 - Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threateni

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 Aethlon Medical,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2025 Aethlon Medical,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2025 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission Fi

INSTRUCTIONS: 1. Enter the current name as on file with the Nevada Secretary of State and enter the Entity or Nevada Business Identif ication Number (NVID). 2. Indicate the current number of authorized shares and par value, if any, and each class or

Exhibit 3.1. INSTRUCTIONS: 1. Enter the current name as on file with the Nevada Secretary of State and enter the Entity or Nevada Business Identif ication Number (NVID). 2. Indicate the current number of authorized shares and par value, if any, and each class or series before the change. 3. Indicate the number of authorized shares and par value, if any of each class or series af ter the change. 4.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2025 Aethlon Medical,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2025 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2025 Aethlon Medica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2025 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission

COMMON STOCK PURCHASE WARRANT AETHLON MEDICAL, Inc.

Exhibit 4.1 COMMON STOCK PURCHASE WARRANT AETHLON MEDICAL, Inc. Warrant Shares: Initial Exercise Date: September 4, 2025 CUSIP: THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after September 4, 2025

September 4, 2025

Exhibit 99.1 September 4, 2025 Aethlon Medical Announces Pricing of $4.5 Million Public Offering SAN DIEGO, Sept. 4, 2025 /PRNewswire/ - Aethlon Medical, Inc. (“Aethlon” or the “Company”) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the pricing of a public offering of an aggregate of 5,000,000

COMMON STOCK PURCHASE WARRANT AETHLON MEDICAL, Inc.

Exhibit 4.3 COMMON STOCK PURCHASE WARRANT AETHLON MEDICAL, Inc. Warrant Shares: 200,000 Initial Exercise Date: September 4, 2025 CUSIP: THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Maxim Group, LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time and f

SECURITIES PURCHASE AGREEMENT

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 4, 2025 between Aethlon Medical, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions s

FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT Aethlon medical, inc.

Exhibit 4.2 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT Aethlon medical, inc. Warrant Shares: [ ˜ ] Issue Date and Initial Exercise Date: September 4, 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth

[Signature page follows]

Exhibit 10.2 CONFIDENTIAL September 4, 2025 Mr. James B. Frakes Chief Executive Officer and Chief Financial Officer Aethlon Medical, Inc. 11555 Sorrento Valley Road, Suite 203 San Diego, CA 92121 Dear Mr. Frakes, This agreement (the “Agreement”) constitutes the agreement between Aethlon Medical, Inc., a Nevada corporation (the “Company”), and Maxim Group LLC (“Maxim” or the “Lead Manager”), that M

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2025 Aethlon Medical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2025 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission F

Up to 4,047,780 Shares of Common Stock Pre-Funded Warrants to Purchase up to 952,220 Shares of Common Stock Warrants to Purchase up to 5,000,000 Shares of Common Stock Placement Agent Warrants to Purchase up to 200,000 shares of Common Stock 6,152,22

AETHLON MEDICAL, INC. S-1 Filed Pursuant to Rule 424(b)(4) Registration No. 333-289745 Up to 4,047,780 Shares of Common Stock Pre-Funded Warrants to Purchase up to 952,220 Shares of Common Stock Warrants to Purchase up to 5,000,000 Shares of Common Stock Placement Agent Warrants to Purchase up to 200,000 shares of Common Stock 6,152,220 Shares of Common Stock Issuable upon the Exercise of the Warr

EFFECT

X0101 EFFECT 33 LIVE 2025-09-04 09:00:00 S-1 0000882291 AETHLON MEDICAL INC 333-289745

MAXIM GROUP LLC 300 Park Avenue, 16th Floor New York, New York 10022

MAXIM GROUP LLC 300 Park Avenue, 16th Floor New York, New York 10022 August 29, 2025 VIA EDGAR CORRESPONDENCE U.

FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT Aethlon medical, inc.

Exhibit 4.11 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT Aethlon medical, inc. Warrant Shares: [ ˜ ] Issue Date and Initial Exercise Date: [ ], 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at an

[Signature page follows]

Exhibit 1.1 CONFIDENTIAL [-], 2025 Mr. James B. Frakes Chief Executive Officer and Chief Financial Officer Aethlon Medical, Inc. 11555 Sorrento Valley Road, Suite 203 San Diego, CA 92121 Dear Mr. Frakes, This agreement (the “Agreement”) constitutes the agreement between Aethlon Medical, Inc., a Nevada corporation (the “Company”), and Maxim Group LLC (“Maxim” or the “Lead Manager”), that Maxim shal

SECURITIES PURCHASE AGREEMENT

Exhibit 10.21 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [-], 2025 between Aethlon Medical, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set fort

AETHLON MEDICAL, INC. COMPUTERSHARE, INC. and COMPUTERSHARE TRUST COMPANY, N.A. Warrant Agent Warrant Agency Agreement Dated as of __, 2025 WARRANT AGENCY AGREEMENT

Exhibit 4.13 AETHLON MEDICAL, INC. and COMPUTERSHARE, INC. and COMPUTERSHARE TRUST COMPANY, N.A. as Warrant Agent Warrant Agency Agreement Dated as of , 2025 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2025 (“Agreement”), by and between Aethlon Medical, Inc., a Nevada corporation (the “Company”), and Computershare Inc., a Delaware corporation (“Computershare Inc.”) and its aff

COMMON STOCK PURCHASE WARRANT AETHLON MEDICAL, Inc.

Exhibit 4.14 COMMON STOCK PURCHASE WARRANT AETHLON MEDICAL, Inc. Warrant Shares: Initial Exercise Date: [-], 2025 CUSIP: THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [-], 2025 (the “Initial E

Aethlon Medical, Inc. 11555 Sorrento Valley Road, Suite 203 San Diego, CA 92121 (619) 941-0360

Aethlon Medical, Inc. 11555 Sorrento Valley Road, Suite 203 San Diego, CA 92121 (619) 941-0360 August 29, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Aethlon Medical, Inc. Registration Statement on Form S-1, as amended File No. 333-289745 REQUEST FOR ACCELERATION OF EFFECTIVENESS Ladies and Gentleman:

COMMON STOCK PURCHASE WARRANT AETHLON MEDICAL, Inc.

Exhibit 4.12 COMMON STOCK PURCHASE WARRANT AETHLON MEDICAL, Inc. Warrant Shares: Initial Exercise Date: [], 2025 CUSIP: THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time and from time to time from and after t

As filed with the Securities and Exchange Commission on August 29, 2025

Table of Contents As filed with the Securities and Exchange Commission on August 29, 2025 Registration Statement No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2025 Aethlon Medical,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2025 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission Fil

Corporate Presentation The Hemopurifier®

Exhibit 99.1 Corporate Presentation The Hemopurifier® FORWARD LOOKING STATEMENTS 2 This investor presentation contains forward - looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe h

Aethlon Medical, Inc. 11555 Sorrento Valley Road, Suite 203 San Diego, CA 92121

Aethlon Medical, Inc. 11555 Sorrento Valley Road, Suite 203 San Diego, CA 92121 August 20, 2025 VIA EDGAR Division of Corporation Finance U.S. Securities & Exchange Commission (the “Commission”) 100 F Street, N.E. Washington, D.C. 20549 Re: Aethlon Medical, Inc. Offering Statement on Form 1-A File No. 024-12551 Ladies and Gentlemen: In accordance with Rule 259 under the Securities Act of 1933, as

Filing Fee Table

Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-1 Aethlon Medical, Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock, $

As filed with the Securities and Exchange Commission on August 20, 2025

Table of Contents As filed with the Securities and Exchange Commission on August 20, 2025 Registration Statement No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PU

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001

Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2025, and Provides Corporate Update Australian Cancer Trial Advances with First Cohort Complete, Amended Protocol, and Promising Preclinical Data Published; Opera

Exhibit 99.1 Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2025, and Provides Corporate Update Australian Cancer Trial Advances with First Cohort Complete, Amended Protocol, and Promising Preclinical Data Published; Operating Expenses Cut by 32% Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, August 13, 2025 - Aethlon Medical, Inc. (the Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 Aethlon Medical,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission Fil

LETTER

July 29, 2025 James Frakes Chief Executive Officer Aethlon Medical, Inc. 11555 Sorrento Valley Road Suite 203 San Diego, CA 92121 Re: Aethlon Medical, Inc. Draft Registration Statement on Form S-1 Filed July 25, 2025 CIK No. 0000882291 Dear James Frakes: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement

Confidential Treatment Requested by Aethlon Medical, Inc.. Pursuant to 17 C.F.R. Section 200.83 As submitted confidentially to the Securities and Exchange Commission on July 25, 2025. This draft registration statement has not been publicly filed with

Table of Contents Confidential Treatment Requested by Aethlon Medical, Inc.. Pursuant to 17 C.F.R. Section 200.83 As submitted confidentially to the Securities and Exchange Commission on July 25, 2025. This draft registration statement has not been publicly filed with the Securities and Exchange Commission, and all information herein remains strictly confidential. Registration Statement No. 333- U

Earnings Script Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update Three Patients Treated in Hemopurifier® Cancer Trial; Indian Regulatory Approval Achieved; Operating Expense

Exhibit 99.1 Earnings Script Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update Three Patients Treated in Hemopurifier® Cancer Trial; Indian Regulatory Approval Achieved; Operating Expenses Reduced; R&D Advances Support Expanded Indications Including Long COVID Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, Jun

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission File

Incentive Compensation Recoupment Policy.

Exhibit 97.1 Aethlon Medical, Inc. Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Aethlon Medical, Inc., a Nevada corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “

Insider Trading Policy.

Exhibit 19.1 AETHLON MEDICAL, INC. INSIDER TRADING POLICY Persons Covered This Insider Trading Policy of Aethlon Medical, Inc. (the “Company”) applies to all directors, officers, other employees and consultants of the Company and any subsidiaries. It also applies to their family members who reside with them, anyone else who lives in their households and any family members who do not live in their

List of Subsidiaries.

Exhibit 21.1 LIST OF SUBSIDIARIES Aethlon Medical Australia Pty Ltd.

Description of Aethlon Medical, Inc.’s Securities.

Exhibit 4.9 DESCRIPTION OF COMMON STOCK The following description summarizes the most important terms of our common stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth in this “Description of Common Stock,” you should refer to our articles of incorporation, as amended, or the articles of inco

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-37487

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Aethlon Medical, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Aethlon Medical, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. __)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. __)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Form of New Warrant

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Form of Inducement Letter

Exhibit 10.1 AETHLON MEDICAL, INC. 11555 Sorrento Valley Road, Suite 203 San Diego, CA 92121 March 16, 2025 To the Holder of May 2024 Class A Warrants and Class B Warrants Re: Inducement Offer to Exercise Existing Class A Warrants and Class B Warrants Dear Holder: Aethlon Medical, Inc. (the “Company”) is pleased to offer to you the opportunity to exercise all the Class A and Class B warrants to pu

Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2025 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission File

AEMD / Aethlon Medical, Inc. / Ikarian Capital, LLC - EX-99.1 V54]17BP=X/Y++CW8ZGW/S>N7.K]:^4F]FHH'5M\=N)-Z>^*PR^,B9^0$:3 MJIOB3&DGQWGL>="PY<:?>@S>>V9FH_Y- GPF?E9L8:\"Y@T_W1WVY=B9P7<\ MB_>7A

begin 644 ck0001669811-ex991.pdf M)5!$1BTQ+C<*"C0@,"!O8FH**$ED96YT:71Y*0IE;F1O8FH*-2 P(&]B:@HH M061O8F4I"F5N9&]B:@HX(# @;V)J"CP\"B]&:6QT97(@+T9L871E1&5C;V1E M"B],96YG=&@@.#,X-# *+TQE;F=T:#$@,S8Q-C7!E("]3=')E86T* M/CX*<['T)8%35U?^Y[[W9MS?[GMDGR4PVLI&$D$PV0#$0!"5! M(F$5$#$L@KBB55&L2JM50:O4O;6M8>(2Q(566VU=P&JKM590J4MKE*]%6I7, M,]],R%!:975[\ WM+/7<[][[S[G+N/7=F7H @!.) !N:IYXPJQ7[S"# M;)8?(/+3\K/EYH 3O

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPOR

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2025 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission F

Aethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update Key Milestone Achieved: First Patient treated in Hemopurifier® Safety, Feasibility, and Dose Finding Study for Solid Tumors

Exhibit 99.1 Aethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update Key Milestone Achieved: First Patient treated in Hemopurifier® Safety, Feasibility, and Dose Finding Study for Solid Tumors Not Responding to Anti-PD-1 Antibodies Patient Enrollment Open at Two Australian for Hemopurifier® Cancer Trial Operating Expenses Signi

Consent of Independent Registered Public Accounting Firm

Exhibit 11.1 Consent of Independent Registered Public Accounting Firm We hereby consent to the use in this Amendment No. 1 to Offering Statement on Form 1-A of our report dated June 27, 2024, relating to the consolidated financial statements of Aethlon Medical, Inc. for the year ended March 31, 2024, which appears in such Offering Statement. Our report includes an explanatory paragraph about the e

PRELIMINARY OFFERING CIRCULAR DATED JANUARY 30, 2025

PRELIMINARY OFFERING CIRCULAR DATED JANUARY 30, 2025 AN OFFERING STATEMENT PURSUANT TO REGULATION A RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 Aethlon Medical,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission Fil

Consent of Independent Registered Public Accounting Firm

Exhibit 11.1 Consent of Independent Registered Public Accounting Firm We hereby consent to the use in this Offering Statement on Form 1-A of our report dated June 27, 2024, relating to the consolidated financial statements of Aethlon Medical, Inc. for the year ended March 31, 2024, which appears in such Offering Statement. Our report includes an explanatory paragraph about the existence of substan

PRELIMINARY OFFERING CIRCULAR DATED DECEMBER 27, 2024

PRELIMINARY OFFERING CIRCULAR DATED DECEMBER 27, 2024 AN OFFERING STATEMENT PURSUANT TO REGULATION A RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

Aethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu

Exhibit 99.1 Aethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu SAN DIEGO, December 20, 2024 - Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided a statement of its investigational medical device with respect to H5N1 avian influenza “Bir

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2024 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission F

As filed with the Securities and Exchange Commission on November 15, 2024

S-8 1 aethlons8.htm S-8 As filed with the Securities and Exchange Commission on November 15, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 13-3632859 (State or other jurisdiction of incorporation) (

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Aethlon Medical, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Aethlon Medical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBE

Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update Achieves Key Milestone with Enrollment of First Two Patients in the Safety, Feasibility, and Dose Finding Study of Aethlo

Exhibit 99.1 Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update Achieves Key Milestone with Enrollment of First Two Patients in the Safety, Feasibility, and Dose Finding Study of Aethlon’s Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies Two Australian Sites Open For Patient Enrollment i

Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon’s Trial is a Safety, Feasibilit

Exhibit 99.1 Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon’s Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO, November 1

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2024 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission F

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2024 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission Fil

Aethlon Medical, Inc. 2020 Equity Incentive Plan, as amended to date, Form of Restricted Stock Grant, Form of Option Grant and Agreement.

Exhibit 10.1 Aethlon Medical, Inc. 2020 Equity Incentive Plan Adopted by the Board of Directors: February 6, 2020 Approved by the Stockholders: September 15, 2020 Amended by the Board: March 24, 2022 Amended by the Board: July 15, 2022 Approved by the Stockholders: September 15, 2022 Amended by the Board: August 6, 2024 Approved by the Stockholders: September 27, 2024 TABLE OF CONTENTS Page 1 GENE

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2024 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2024 Aethlon Medica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2024 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission

Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India Aethlon Medical Granted Full Ethics Approval from the Medanta Institutional Ethics Committee for a Safety, Feasibility, and Dose Finding Study of its Hemopurifier® in

Exhibit 99.1 Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India Aethlon Medical Granted Full Ethics Approval from the Medanta Institutional Ethics Committee for a Safety, Feasibility, and Dose Finding Study of its Hemopurifier® in Cancer Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO, September 19, 2024 - Aethlon Medical, Inc. (Nasdaq: A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini

ANNUAL REPORT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-37487

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 ☐ TRANSIT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FI

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission Fil

Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update Received Two Australian Ethics Committee Approvals for a Safety, Feasibility, and Dose Finding Study of Aethlon’s Hemopurifier®

Exhibit 99.1 Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update Received Two Australian Ethics Committee Approvals for a Safety, Feasibility, and Dose Finding Study of Aethlon’s Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies; Expects to Open Patient Enrollment in October of 2024 Achieved Sig

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001

Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier® Cancer Trial Bellberry Human Research Ethics Committee Granted Full Ethics Approval to the Pindara Private Hospital for a Safety, Feasibility, and Dose Finding Study of Aethl

Exhibit 99.1 Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier® Cancer Trial Bellberry Human Research Ethics Committee Granted Full Ethics Approval to the Pindara Private Hospital for a Safety, Feasibility, and Dose Finding Study of Aethlon’s Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO, August 12, 2024 - Aethlon Medical, Inc

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission Fil

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2024 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission File N

Letter from Baker Tilly US, LLP to the Securities and Exchange Commission, dated July 3, 2024.

Exhibit 16.1 Baker Tilly Advisory Group, LP 3655 Nobel Dr,Suite 300 San Diego, CA 92122 United States of America T: +1 (858) 597 4100 F: +1 (858) 597 4111 bakertilly.com July 3, 2024 Securities and Exchange Commission 100 F Street, N E Washington, DC 20549 Dear Ladies and Gentlemen: We are the former independent registered public accounting firm for Aethlon Medical, Inc. (the “Company”). We have r

Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update Conference Call to be Held Today at 4:30 p.m. ET

Exhibit 99.1 Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, June 27, 2024 - Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for it

Incentive Compensation Recoupment Policy.

Exhibit 97.1 Aethlon Medical, Inc. Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Aethlon Medical, Inc., a Nevada corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “

List of Subsidiaries.

Exhibit 21.1 List of Subsidiaries Subsidiary Percentage Owned by Aethlon Medical, Inc. Jurisdiction of Incorporation Aethlon Medical Australia Pty Ltd 100% Australia

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-37487

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 Aethlon Medical, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 Aethlon Medical, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission File N

Form of Class A Warrant to Purchase Common Stock, issued on May 17, 2024.

Exhibit 4.1 CLASS A COMMON STOCK PURCHASE WARRANT AETHLON MEDICAL, Inc. Warrant Shares: Initial Exercise Date: May 17, 2024 CUSIP: 00808Y 117 THIS CLASS A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or af

Form of Placement Agent Warrant to Purchase Common Stock, issued on May 17, 2024.

Exhibit 4.4 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT AETHLON MEDICAL, Inc. Warrant Shares: 324,000 Initial Exercise Date: November 15, 2024 CUSIP: 00808Y 133 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Maxim Partners LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission File N

Form of Class B Warrant to Purchase Common Stock, issued on May 17, 2024.

Exhibit 4.2 CLASS B COMMON STOCK PURCHASE WARRANT AETHLON MEDICAL, Inc. Warrant Shares: Initial Exercise Date: May 17, 2024 CUSIP: 00808Y 141 THIS CLASS B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or af

Aethlon Medical Announces Pricing of $4.7 Million Public Offering

Exhibit 99.1 Aethlon Medical Announces Pricing of $4.7 Million Public Offering SAN DIEGO, May 15, 2024 - Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the pricing of a public offering of an aggregate of 8,100,000 shares of its common stock (or pre-funded warrants in lieu t

Form of Pre-Funded Warrant to Purchase Common Stock, issued on May 17, 2024.

Exhibit 4.3 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT AETHLON MEDICAL, INC. Warrant Shares: Issue Date and Initial Exercise Date: May 17, 2024 CUSIP: 00808Y 125 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter se

2,450,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 5,650,000 Shares of Common Stock Class A Warrants to Purchase up to 8,100,000 Shares of Common Stock Class B Warrants to Purchase up to 8,100,000 Shares of Common Stock Placement

Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-278188 PROSPECTUS 2,450,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 5,650,000 Shares of Common Stock Class A Warrants to Purchase up to 8,100,000 Shares of Common Stock Class B Warrants to Purchase up to 8,100,000 Shares of Common Stock Placement Agent Warrants to Purchase up to 324,000 Shares of Common St

As filed with the Securities and Exchange Commission on May 15, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-effective Amendment No. 1 FORM S-1 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 Aethlon Medical, In

Registration No. 333-278188 As filed with the Securities and Exchange Commission on May 15, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-effective Amendment No. 1 To FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 3826 13-3632859 (State or other jurisdiction of

Form of Securities Purchase Agreement.

Exhibit 10.20 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [ ], 2024 between Aethlon Medical, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set fort

As filed with the Securities and Exchange Commission on May 13, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 FORM S-1/A REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 Aethlon Medical, Inc. (Exact nam

Table of Contents Registration No. 333-278188 As filed with the Securities and Exchange Commission on May 13, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 To FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 3826 13-3632859 (State or other jurisdictio

CLASS [A] [B] COMMON STOCK PURCHASE WARRANT AETHLON MEDICAL, Inc.

Exhibit 4.6 CLASS [A] [B] COMMON STOCK PURCHASE WARRANT AETHLON MEDICAL, Inc. Warrant Shares: Initial Exercise Date: May [], 2024 CUSIP: THIS CLASS [A] [B] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 Aethlon Medical, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission File N

Aethlon Medical, Inc. 11555 Sorrento Valley Road, Suite 203 San Diego, California 92121

Aethlon Medical, Inc. 11555 Sorrento Valley Road, Suite 203 San Diego, California 92121 May 10, 2024 Via Edgar U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Robert Augustin Re: Aethlon Medical, Inc. Registration Statement on Form S-1, as amended (File No. 333-278188) Acceleration Request Requested Date: May 14, 2024 Requeste

MAXIM GROUP LLC 300 Park Avenue, 16th Floor New York, New York 10022

MAXIM GROUP LLC 300 Park Avenue, 16th Floor New York, New York 10022 May 10, 2024 VIA EDGAR CORRESPONDENCE U.

Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma Translational Study Provides Pre-Clinical Evidence to Support The Design of a Phase 1 Study of

Exhibit 99.1 Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma Translational Study Provides Pre-Clinical Evidence to Support The Design of a Phase 1 Study of the Hemopurifier In Cancer Patients With Solid Tumors Treated With Anti-PD-1 Antibodies SAN DIEGO, May 10, 2024 - Aethlon Medical, Inc. (

Nasdaq: AEMD www.AethlonMedical.com Corporate Presentation April 2024

Exhibit 99.1 Nasdaq: AEMD www.AethlonMedical.com Corporate Presentation April 2024 FORWARD LOOKING STATEMENTS This investor presentation contains forward - looking statements, as that term is defined in the Private Securities Litigation Ref orm Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, a s a mended, wh

As filed with the Securities and Exchange Commission on April 25, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 FORM S-1/A REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 Aethlon Medical, Inc. (Exact n

Table of Contents Registration No. 333-278188 As filed with the Securities and Exchange Commission on April 25, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 To FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 3826 13-3632859 (State or other jurisdict

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 AETHLON MEDICAL, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission File

Form of Warrant to Purchase Common Stock.

Exhibit 4.6 COMMON STOCK PURCHASE WARRANT AETHLON MEDICAL, Inc. Warrant Shares: Initial Exercise Date: [], 2024 CUSIP: THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after (the “Initial Exercise Date

Form of Securities Purchase Agreement

Exhibit 10.20 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [ ], 2024 between Aethlon Medical, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set fort

Form of Placement Agent Warrant to Purchase Common Stock

Exhibit 4.8 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT AETHLON MEDICAL, Inc. Warrant Shares: Initial Exercise Date: [], 2024 CUSIP: THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time and from time to time f

As filed with the Securities and Exchange Commission on April 5, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 FORM S-1/A REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 Aethlon Medical, Inc. (Exact na

Table of Contents Registration No. 333-278188 As filed with the Securities and Exchange Commission on April 5, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 To FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 3826 13-3632859 (State or other jurisdicti

Form of Pre-Funded Warrant to Purchase Common Stock

Exhibit 4.7 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT AETHLON MEDICAL, INC. Warrant Shares: [l] Issue Date and Initial Exercise Date: [l], 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any t

LETTER

United States securities and exchange commission logo March 28, 2024 James Frakes Interim Chief Executive Officer Aethlon Medical, Inc.

As filed with the Securities and Exchange Commission on March 22, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 Aethlon Medical, Inc. (Exact name of registrant

Table of Contents Registration No. 333- As filed with the Securities and Exchange Commission on March 22, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 3826 13-3632859 (State or other jurisdiction of incorporation or org

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Aethlon Medical, Inc.

Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update Conference Call to be Held Today at 4:30 p.m. ET

Exhibit 99.1 Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, February 14, 2024 - Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third q

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2024 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPOR

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER

Amendment No. 1 to Executive Employment Agreement, effective as of November 7, 2023, by and between the Company and Guy F. Cipriani

Exhibit 10.2 AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into effective as of November 7, 2023 (the “Effective Date”) by and between Aethlon Medical, Inc., a Nevada corporation (the “Company”), and Guy F. Cipriani, an individual resident in the State of California (the “Employee”) (the Company and t

Amendment No. 1 to Executive Employment Agreement, effective as of November 7, 2023, by and between the Company and James B. Frakes.

Exhibit 10.1 AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into effective as of November 7, 2023 (the “Effective Date”) by and between Aethlon Medical, Inc., a Nevada corporation (the “Company”), and James B. Frakes, an individual resident in the State of California (the “Employee”) (the Company and t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2023 AETHLON MEDICAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2023 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission F

Separation Agreement between the Company and Dr. Fisher, effective as of November 27, 2023.

Exhibit 10.1 11555 Sorrento Valley Road Suite 203 San Diego, CA 92121 Phone 619-941-0360 November 7, 2023 Charles J. Fisher, Jr. M.D. Re:Separation Agreement Dear Chuck: This letter sets forth the substance of the separation agreement (the “Agreement”) that Aethlon Medical, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. Separation. Your employment termination date

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 AETHLON MEDICAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBE

Aethlon Medical Announces Fiscal Second Quarter Financial Results and Provides Corporate Update Conference Call to be Held Today at 4:30 p.m. ET

Exhibit 99.1 Aethlon Medical Announces Fiscal Second Quarter Financial Results and Provides Corporate Update Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, November 14, 2023 - Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today reported financial results for its fiscal second

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 AETHLON MEDICAL,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 Aethlon Medical,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction of incorporation) (Commission Fil

Aethlon Announces Reverse Stock Split

Exhibit 99.1 Aethlon Announces Reverse Stock Split SAN DIEGO, October 4, 2023 - Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company's common stock, effective at 5:00 p.m. ET on October 4, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2023 AETHLON MEDICA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2023 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 AETHLON MEDICAL,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001

Aethlon Medical Announces Fiscal First Quarter Financial Results and Provides Corporate Update Conference Call to be Held Today at 4:30 p.m. ET

Exhibit 99.1 Aethlon Medical Announces Fiscal First Quarter Financial Results and Provides Corporate Update Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, August 10, 2023 - Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today reported financial results for its fiscal first qua

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini

ARS

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-37487

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2023 AETHLON MEDICAL, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2023 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 AETHLON MEDICAL, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission File

List of Subsidiaries

Exhibit 21.1 List of Subsidiaries Subsidiary Percentage Owned by Aethlon Medical, Inc. Jurisdiction of Incorporation Aethlon Medical Australia Pty Ltd 100% Australia

Amendment No. 1 to Executive Employment Agreement, by and between Aethlon Medical, Inc. and Lee D. Arnold, Ph.D., dated May 1, 2023.

Exhibit 10.18 AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into as of May 1, 2023 (the “Effective Date”) by and between Aethlon Medical, Inc., a Delaware corporation (the “Company”), and Lee D. Arnold, Ph.D., an individual resident in the State of California (the “Employee”) (the Company and the Empl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-37487

Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update Conference Call to be Held Today at 4:30pm ET

Exhibit 99.1 Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update Conference Call to be Held Today at 4:30pm ET SAN DIEGO, June 28, 2023 - Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today reported financial results for its fiscal year ended March 31

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2023 AETHLON MEDICAL, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2023 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 ☐ TRANSITION REPOR

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER

Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update

Exhibit 99.1 Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update SAN DIEGO, February 13, 2023 - Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its third quarter ended December 31, 2022 and provided an upd

Executive Employment Agreement, by and between Aethlon Medical, Inc. and Lee D. Arnold, Ph.D., dated February 1, 2023.

Exhibit 10.1 AETHLON MEDICAL, INC. EXECUTIVE EMPLOYMENT AGREEMENT for LEE D. ARNOLD, Ph.D. This Executive Employment Agreement (this “Agreement”) is made and entered into as of February 1, 2023 (the “Effective Date”), by and between Lee D. Arnold, Ph.D. (“Employee”) and Aethlon Medical, Inc. (the “Company”). 1. Employment by the Company. 1.1 Start Date and Position. Employee’s employment with the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2023 AETHLON MEDICAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2023 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBE

Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update

Exhibit 99.1 Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update SAN DIEGO, Nov. 14, 2022 - Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its second quarter ended September 30, 2022 and provided an upda

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2022 AETHLON MEDICAL,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2022 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission Fi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2022 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission

$6,625,000 Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-259909 PROSPECTUS SUPPLEMENT (To Prospectus Dated October 21, 2021) $6,625,000 Common Stock This prospectus supplement relates to the offer, issuance and sale from time to time of common stock having an aggregate offering price of up to $6,625,000 through H.C. Wainwright & Co., LLC, or Wainwright, as sales agent. These sales,

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2022 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission

Articles of Incorporation, as amended.

EXHIBIT 3.1 ARTICLES OF INCORPORATION OF BISHOP EQUITIES, INC. Article I - The Corporation The name of the corporation is Bishop Equities, Inc. (the "Corporation") and it is hereby incorporated pursuant to the laws of the State of Nevada. Article II - Duration of Existence The Corporation shall have perpetual existence. Article IV - Purposes and Powers of Corporation The Corporation shall have unl

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Aethlon Medical, Inc.

As filed with the Securities and Exchange Commission on September 19, 2022

As filed with the Securities and Exchange Commission on September 19, 2022 Registration No.

We have marked with an asterisk (*) those risk factors that are new risk factors or ones containing substantive changes from the similarly titled risk factors included in our 2022 Annual Report.

Exhibit 99.2 As used in this Exhibit 99.2, unless the context indicates otherwise, references to ?the Company,? ?we,? ?us,? ?our? and similar references refer to Aethlon Medical, Inc. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Company?s Annual Report on Form 10-K for the fiscal year ended March 31, 2022 (?2022 Annual Report?), filed with the Secur

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission

Aethlon Medical, Inc. 2020 Equity Incentive Plan Adopted by the Board of Directors: February 6, 2020 Approved by the Stockholders: September 15, 2020 Amended by the Board: March 24, 2022 Amended by the Board: July 15, 2022 Approved by the Stockholder

Exhibit 99.1 Aethlon Medical, Inc. 2020 Equity Incentive Plan Adopted by the Board of Directors: February 6, 2020 Approved by the Stockholders: September 15, 2020 Amended by the Board: March 24, 2022 Amended by the Board: July 15, 2022 Approved by the Stockholders: September 15, 2022 1. General 1 2. Shares Subject to the Plan 1 3. Eligibility and Limitations 2 4. Options and Stock Appreciation Rig

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission File

Aethlon Medical Announces First Quarter Financial Results and Provides Corporate Update

Exhibit 99.1 Aethlon Medical Announces First Quarter Financial Results and Provides Corporate Update SAN DIEGO, Aug. 9, 2022 - Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its first quarter ended June 30, 2022 and provided an update on re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PU

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001

Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-259909 AMENDMENT NO. 1 DATED AUGUST 2, 2022 To Prospectus Supplement dated March 24, 2022 (To Prospectus Dated October 21, 2021) $15,000,000 Common Stock We previously entered into a certain sales agreement, or the sales agreement, with H.C. Wainwright & Co., LLC, or Wainwright, acting as sales agent. As of August 2, 2022, we have sold 6,865,83

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update

Exhibit 99.1 Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update SAN DIEGO June 28, 2022 - Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening infectious diseases, today reported financial results for its fiscal year ended March 31, 2022 and provided an update on rec

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2022 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission File

Amendment to SBIR Phase II Award Contract, by and among Aethlon Medical, Inc., the National Institutes of Health and the National Cancer Institute, dated October 28, 2020.

Exhibit 10.8 AMENDMENT OF SOLICITATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 4 2. AMENDMENT/MODICATION NO. P00001 3. EFFECTIVE DATE See Block 16c 4. REQUISITION/PURCHASE REQ. NO. 5. PROJECT NO. (if applicable) 6. ISSUED BY CODE NCI-EXEC 7. ADMINISTERED BY (if other than Item 6) CODE NCI National Institutes of Health National Cancer Institute Bethesda, MD 20892-7511 National Institutes of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-37487

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission File

$15,000,000 Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-259909 PROSPECTUS SUPPLEMENT (To Prospectus Dated October 21, 2021) $15,000,000 Common Stock This prospectus supplement relates to the offer, issuance and sale from time to time of common stock having an aggregate offering price of up to $15,000,000 through H.C. Wainwright & Co., LLC, or Wainwright, as sales agent. These sales

At the Market Offering Agreement, dated March 24, 2022, by and between Aethlon Medical, Inc. and H.C. Wainwright & Co., LLC

Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT March 24, 2022 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Aethlon Medical, Inc., a corporation organized under the laws of Nevada (the ?Company?), confirms its agreement (this ?Agreement?) with H.C. Wainwright & Co., LLC (the ?Manager?) as follows: 1. ? Definitions. The terms that follow, when used in this

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission File

Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update

Exhibit 99.1 Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update SAN DIEGO Feb. 14, 2022 - Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious diseases, today reported financial results for its third quarter ended December 31, 2021 and provided an update on recent developments. Company Upd

Aethlon Medical, Inc. Amended and Restated Non-Employee Director Compensation Policy, as Modified on February 10, 2022

EXHIBIT 10.2 Aethlon Medical, Inc. Amended and Restated Non-Employee Director Compensation Policy February 10, 2022 Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of or consultant to Aethlon Medical, Inc. (the ?Company?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Amended and Resta

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 ☐ TRANSITION REPOR

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2022 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission F

AEMD / Aethlon Medical, Inc. / Empery Asset Management, LP - AETHLON MEDICAL, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aethlon Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 00808Y307 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which th

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission Fi

Lease between Aethlon Medical, Inc. and San Diego Inspire 5, LLC, effective October 27, 2021.

Exhibit 10.1 LEASE SOVA CENTRAL SCIENCE DISTRICT SAN DIEGO INSPIRE 5, LLC, a Delaware limited liability company as Landlord, and AETHLON MEDICAL, INC., a Nevada corporation, as Tenant. Table of Contents Page 1 PREMISES, BUILDING, PROJECT, AND COMMON AREAS 5 2 LEASE TERM; OPTION TERM 6 3 BASE RENT 8 4 ADDITIONAL RENT 8 5 USE OF PREMISES 14 6 SERVICES AND UTILITIES 20 7 REPAIRS 23 8 ADDITIONS AND AL

Amendment to SBIR Phase II Award Contract, effective as of July 1, 2020, by and among Aethlon Medical, Inc., the National Institutes of Health and the National Cancer Institute.

Exhibit 10.2

Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update

Exhibit 99.1 Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update SAN DIEGO Nov. 9, 2021 - Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious diseases, today reported financial results for its second quarter ended September 30, 2021 and provided an update on recent developments. Company U

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBE

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2021 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction (Commission File Number) (IRS Em

As filed with the Securities and Exchange Commission on September 30, 2021

As filed with the Securities and Exchange Commission on September 30, 2021 Registration No.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2021 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction (Commission File Number) (IRS

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission File

Aethlon Medical Announces First Quarter Financial Results and Provides Corporate Update

Exhibit 99.1 Aethlon Medical Announces First Quarter Financial Results and Provides Corporate Update SAN DIEGO, CA, August 9, 2021 - Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its first quarter ended June 30, 2021 and provided an update on recent de

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PU

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001

Definitive Proxy Statement on Schedule 14A

SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials Soliciting Material Pursuant to ? 240.

SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ? 240.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2021 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction (Commission File Number) (IRS Emplo

Aethlon Medical, Inc. Amended and Restated Non-Employee Directors Compensation Policy, as Modified on October 30, 2020.

EXHIBIT 10.12 Aethlon Medical, Inc. Amended and Restated Non-Employee Director Compensation Policy October 30, 2020 Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of or consultant to Aethlon Medical, Inc. (the ?Company?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Amended and Resta

Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update

Exhibit 99.1 Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update SAN DIEGO, CA, June 24, 2021 - Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its fiscal year ended March 31, 2021 and provided an update on recent de

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2021 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-37487

Aethlon Medical, Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aethlon Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 00808Y307 (CUSIP Number) June 10, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Sc

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37487 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission File

SECURITIES PURCHASE AGREEMENT

Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of June 10, 2021, between Aethlon Medical, Inc., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions set

Aethlon Medical, Inc. 1,380,555 shares of Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-237269 PROSPECTUS SUPPLEMENT (To Prospectus dated March 30, 2020) Aethlon Medical, Inc. 1,380,555 shares of Common Stock Aethlon Medical, Inc. is offering 1,380,555 shares of our common stock pursuant to this prospectus supplement and accompanying prospectus to certain institutional investors. The last reported sale price of o

405 Lexington Avenue * New York, NY 10174 * (212) 895-3500 * (800) 724-0761 * fax (212) 895-3783 * www.maximgrp.com

Exhibit 99.2 June 10, 2021 James B. Frakes Chief Financial Officer Aethlon Medical, Inc. 9635 Granite Ridge Drive, Suite 100 San Diego, CA 92123 Dear Mr. Frakes, This letter (the ?Agreement?) constitutes the agreement between Aethlon Medical, Inc. (the ?Company?) and Maxim Group, LLC (?Maxim? or the ?Lead Manager?), that Maxim shall serve as the exclusive lead placement agent for the Company, on a

Aethlon Medical Announces $12.425 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Exhibit 99.3 Aethlon Medical Announces $12.425 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules SAN DIEGO, June 10, 2021 /PRNewswire/ - Aethlon Medical, Inc. (Nasdaq:AEMD), a medical device technology company focused on unmet needs in global health, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase in a r

$5,080,000 Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-237269 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 30, 2020) $5,080,000 Common Stock This prospectus supplement relates to the offer, issuance and sale from time to time of common stock having an aggregate offering price of up to $5,080,000 through H.C. Wainwright & Co., LLC, or Wainwright, as sales agent. These sales, if any, will be made

At the Market Offering Agreement, March 22, 2021, by and between Aethlon Medical, Inc. and H.C. Wainwright & CO., LLC.

EX-1.1 2 aethlonex0101.htm AT THE MARKET OFFERING AGREEMENT, MARCH 22, 2021, BY AND BETWEEN AETHLON MEDICAL, INC. AND H.C. WAINWRIGHT & CO., LLC. Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT March 22, 2021 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Aethlon Medical, Inc., a corporation organized under the laws of Nevada (the “Company”), confirms its ag

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2021 AETHLON MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 333-237269 13-3632859 (State or Other Jurisdiction of Incorporation) (Commission Fil

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 2)* AETH

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 2)* AETHLON MEDICAL, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00808Y307 (CUSIP Number) December 31, 2020

Quarterly Report - FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER

Executive Employment Agreement between the Company and Guy Cipriani, dated January 1, 2021.

Exhibit 10.5 AETHLON MEDICAL, INC. EXECUTIVE EMPLOYMENT AGREEMENT for GUY F. CIPRIANI This Executive Employment Agreement (this “Agreement”) is made and entered into as of January 1, 2020 (the “Effective Date”), by and between Guy F. Cipriani (“Employee”) and Aethlon Medical, Inc. (the “Company”). 1. Employment by the Company. 1.1 Start Date and Position. Employee’s employment with the Company sha

Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2021 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) Nevada 001-37487 13-3632859 (State or other jurisdiction (Commission File Number) (IRS E

Eighth Amendment to Standard Industrial Net Lease, by and between the Company and San Diego Inspire 1, LLC., effective December 7, 2020.

Exhibit 10.4 eighth AMENDMENT TO STANDARD INDUSTRIAL NET lease BETWEEN SAN DIEGO INSPIRE 1, LLC AND AETHLON MEDICAL, INC. THIS EIGHTH AMENDMENT TO STANDARD INDUSTRIAL NET LEASE (this “Eighth Amendment”) is dated as of November 9, 2020, by and between SAN DIEGO INSPIRE 1, LLC, a Delaware limited liability company (“Landlord”), and AETHLON MEDICAL, INC., a Nevada corporation (“Tenant”). RECITALS A.

Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update

Exhibit 99.1 Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update SAN DIEGO, CA, February 10, 2021 - Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device therapeutic company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its third quarter ended December 31, 2020 and provided an upda

Lease, by and between the Company and San Diego Inspire 1, LLC. and San Diego Inspire 2, LLC, effective December 7, 2020.

Exhibit 10.3 LEASE SOVA CENTRAL SCIENCE DISTRICT SAN DIEGO INSPIRE 1, LLC, a Delaware limited liability company and SAN DIEGO INSPIRE 2, LLC, a Delaware limited liability company collectively, as Landlord, and AETHLON MEDICAL, INC., a Nevada corporation, as Tenant. TABLE OF CONTENTS Page 1. PREMISES, BUILDING, PROJECT, AND COMMON AREAS 6 2. LEASE TERM; OPTION TERM 8 3. BASE RENT 10 4. ADDITIONAL R

Executive Employment Agreement between the Company and Steven P. LaRosa, MD, dated January 4, 2021.

Exhibit 10.6 AETHLON MEDICAL, INC. EXECUTIVE EMPLOYMENT AGREEMENT for STEVEN P. LAROSA, MD This Executive Employment Agreement (this “Agreement”) is made and entered into as of January 4, 2021 (the “Effective Date”), by and between Steven P. LaRosa, MD (“Employee”) and Aethlon Medical, Inc. (the “Company”). 1. Employment by the Company. 1.1 Start Date and Position. Employee’s employment with the C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Aethlon Medical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Secur

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Aethlon Medical, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 00808Y307 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r

Aethlon Medical, Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aethlon Medical, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 00808Y307 (CUSIP Number) December 31, 2020 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which th

1 NASDAQ: AEMD Investor Presentation January 2021 2 This investor presentation contains forward - looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the ability to enroll

Exhibit 99.1 1 NASDAQ: AEMD Investor Presentation January 2021 2 This investor presentation contains forward - looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the ability to enroll patients in the Early Feasibility Studies; the ability to successfully complete the Early Feasibility Studies and achieve the endpoints